AAV-NLS-PGC1α4
AAV-NLS-PGC1α4 has been studied in 1 paper since 2023: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Aug 16, 2023: “AAV-Mediated nuclear localized PGC1α4 delivery in muscle ameliorates sarcopenia and aging-associated metabolic dysfunctions”.
1 paper studies it3 findingsUpdated
- 1 lab in 1 country
- Funders: East China Normal University and 5 more
- Animals1
What did studies of AAV-NLS-PGC1α4 find?
3Studies of AAV-NLS-PGC1α4 measured 3 outcomes; the most studied are glucose uptake (1 study), insulin resistance (1) and grip strength (1).
Glucose uptake
upin mice1
1 study
Glucose uptake
upin mice1
AAV-NLS-PGC1α4 increases glucose uptake in mice.
“Mechanistically, we demonstrated that NLS-PGC-1α4 improved insulin signaling and enhanced glucose uptake in skeletal muscle.”
Animalsskeletal muscle
Aging cell
Insulin resistance
downin mice1
1 study
Insulin resistance
downin mice1
AAV-NLS-PGC1α4 decreases insulin resistance in mice.
“and alleviate age-associated adiposity, insulin resistance and hepatic steatosis, accompanied with altered gene signatures.”
Animalsgastrocnemius muscle
Aging cell
Grip strength
upin mice1
1 study
Grip strength
upin mice1
AAV-NLS-PGC1α4 improves grip strength in mice.
“we found that it could improve sarcopenia with grip strength, muscle weights, fiber size and molecular phenotypes”
Animalsgastrocnemius muscle
Aging cell